OTC · ACORQ
Acorda Therapeutics, Inc.
$0.01-$0.00 (-24.81%)
Acorda Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.94% below the high.
Loading market information…
OTC · NNMX · USD
Stock price, earnings
Quote as of Apr 8, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Nanomix Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Nanomix Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Boston Therapeutics, Inc. focuses on the discovery, production, and commercialization of therapeutic drugs aimed at fulfilling critical unmet medical needs in the areas of diabetes and inflammatory diseases. The company's pipeline features BTI-320, a non-systemic, carbohydrate-based tablet currently in Phase II clinical trials, which is being developed to reduce post-meal blood glucose levels in patients with pre-diabetes and type 2 diabetes. They also have IPOXYN, an injectable medication designed to prevent tissue necrosis and address conditions caused by low oxygen, such as diabetic foot ulcers and other related vascular or neurological complications. Additionally, Boston Therapeutics is progressing with BTI-410, a peptide injectable compound also in Phase II clinical development, intended to stimulate beta cell maturation in the pancreas. This could potentially serve as a new insulin-producing cell agent for individuals with type 2 diabetes and type 1 patients on immunosuppression therapy following a kidney transplant. Complementing its pharmaceutical endeavors, the company offers SUGARDOWN, a non-systemic, polysaccharide-based dietary supplement designed to support healthy blood glucose management, and OXYFEX, a veterinary application that acts as an oxygen delivery agent, similar to a red blood cell replacement, for treating ischemia, trauma, and blood loss during surgical procedures. The firm further extends its offerings to include Automatic Retinal Image Analysis (ARIA), a diagnostic tool used for screening cardiovascular risks, including stroke. Boston Therapeutics, Inc. maintains its headquarters in Lawrence, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:18 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.01-$0.00 (-24.81%)
Acorda Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.94% below the high.
$0.00$0.00 (0.0%)
Advanzeon Solutions, Inc.: Healthcare · Medical - Care Facilities.
$0.00$0.00 (0.0%)
MagForce AG: Healthcare · Medical - Devices.
$0.01$0.00 (0.0%)
NeonMind Biosciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.67% below the high.
$0.00-$0.00 (0.0%)
MobileSmith, Inc.: Healthcare · Medical - Healthcare Information Services.
$0.00$0.00 (0.0%)
EastWest Bioscience Inc.: Healthcare · Medical - Pharmaceuticals.
$0.00$0.00 (0.0%)
Gelesis Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.0% below the high.
$0.00-$0.04 (-99.5%)
E-Qure Corp.: Healthcare · Medical - Devices.
